Effect of Orlistat in Body Composition
- Registration Number
- NCT00752726
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.
- Detailed Description
Large amounts of VAT (adipose tissue surrounding the viscera of the organs), is known to be associated with increased risk of heart disease and diabetes. Orlistat (tetrahydrolipstatin or THL) inhibits gastrointestinal lipase and reduces the absorption of dietary fat. The purpose of this study is to to determine if a 24 week weight loss program with orlistat 60 mg would produce greater changes in adipose tissue depots (specifically VAT) compared to placebo. This study will use the Echo MRI technology across multiple sites to measure total fat mass. EchoMRI is a non invasive method ideally suited for studies which track changes in human body composition over time, with measuring times of less than 3 minutes and no radiation exposure.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 131
- Aged 18-60 years inclusive
- Body Mass Index (BMI): BMI in the range of 25.0-34.9 kg/m^2
- Waist circumference:
Females: > 35 inches Males: > 40 inches
-
Diet:
- Normal eating habits, consuming 3 meals a day (breakfast, lunch and dinner)
- Willing to follow a hypocaloric diet during the study to achieve weight loss
- Willing to take a daily multivitamin for the duration of the study.
-
General Health:Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination
-
Pregnant and/ or Breast-feeding women
-
Diet/Exercise:Currently on a special diet or who cannot fulfill the dietary requirements of the study.
-
Smoking History:a) Smoking cessation within the past 6 months b) Current Smokers
-
Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials and study foods (or closely related compounds) or any of their stated ingredients.
-
Medication:
a) Currently taking medication for weight loss or appetite control. b) Previous Xenical® (orlistat) or alli® use within 3 months of screening date c) Currently taking medication or supplements that influence intestinal transit time and other stool formation parameters or influences cramping (e.g., Anticholinergics (such as atropine) or cholinergics (such as physostigmine), phenothiazines, tricyclic antidepressants, opioid analgesics (including loperamide), calcium channel antagonists, clonidine, cisapride, octreotide. Also, any laxative or antidiarrheal product). d) Currently taking or withdrawn during the past 6 months any drugs with significant impact on body weight (e.g. serotoninergically acting drugs, antidepressants, central adrenergically acting drugs, drugs inhibiting digestion and absorption, appetite suppressants, metformin) e) Currently taking Cyclosporine, Warfarin or Amiodarone HCL
-
Disease/Surgery:
a) History of gastrointestinal disease (e.g., irritable bowel syndrome, diarrhea, inflamed bowel, steatorrhea/fat malabsorption, hemorrhoids, incontinence, pancreatitis). b) History of psychological disorder, including eating disorders such as anorexia nervosa and bulimia c) History of neurological disorder (e.g. seizures, parkinson's disease, Alzheimer's disease) d) History of hypo/hyperthyroidism unless euthyroid and controlled on a stable dose of medication for at least 6 months. e) History of surgery for weight loss f) Uncontrolled hypertension g) Heart Disease h) Diabetes Mellitus (Type 1 and 2) (Fasting Blood Glucose >126 mg/dL)
-
Participant has a known history of panic attacks and/or claustrophobia or other conditions precluding safe EchoMRI, CT or other scanning modalities according to local guidelines, (e.g., pacemaker, hearing aid, metallic body piercing and/or other metal implants) or in the opinion of the Investigator the participant exceeds size limitations for the instruments.
-
Participant has had a weight loss or gain of greater than or equal to 3 kg in the 3 months prior to screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Orlistat Orlistat Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day Placebo Placebo Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 24 in Abdominal VAT Mass Baseline to week 24 VAT was measured by the computed tomography (CT) scan.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 12 in Abdominal VAT Mass Baseline to week 12 Abdominal VAT mass from baseline to week 12 was measured by CT scan.
Change From Baseline to Week 24 in Body Weight Baseline to week 24 Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded.
Change From Baseline to Week 24 in Total Fat Mass Baseline to week 24 Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI).
Change From Baseline to Week 24 in Percentage Body Fat Baseline to week 24 Body fat was assessed through Bioelectrical Impedance Analysis (BIA).
Change From Baseline to Week 24 in Waist Circumference Baseline to week 24 Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position.
Change From Baseline to Week 24 in Percentage Liver Fat Baseline to week 24 For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS).
Change From Baseline to Week 24 in Liver Fat Baseline to week 24 The liver fat was measured by CT scan in Hounsfield Units (HU).
Change From Baseline to Week 24 in Total Calories Expended for Physical Activity Baseline to week 24 Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity
Change From Baseline to Week 24 in Quality of Life (QoL) Scores. Baseline to week 24 QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life.
Selectivity Index at Week 24 Baseline to week 24 The selectivity index (SI) was used as a measure of orlistat's ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass.
Trial Locations
- Locations (3)
Pennington Biomedical Research Center
🇺🇸Baton Rouge, Louisiana, United States
Sahlgrenska Academy
🇸🇪Goteborg, West Gothland, Sweden
Duke Clinical Research Unit
🇺🇸Durham, North Carolina, United States